Hormonal-Receptors-Positive and HER2-Negative Patients with Metastatic Breast Cancer Treated with First-Line Palbociclib and Hormonal Therapy: Impact of First-Cycle Neutropenia and Dose Reduction on Therapeutic Outcome

Table 5

OS multivariate.

Parameters	HR	95% confidence interval		value
		Lower boundary	Upper boundary
Allred score	2.22	1.10	4.50	0.026
PR-status	1.69	0.78	3.69	0.81
Site of metastasis	1.64	0.26	8.17	0.67
Site of metastasis (single)	0.22	0.053	0.935	0.04
Palbociclib dose reduction	1.62	0.83	3.17	0.16